U.S. Markets closed

Simulations Plus, Inc. (SLP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
15.10-0.15 (-0.98%)
At close: 4:00PM EDT

15.10 0.00 (0.00%)
After hours: 4:45PM EDT

People also watch
SILCSPNSGVPDWCHSGRP
  • B
    Bill
    Bill
    What happen,just brought in and next day drop.30 in the morning and haven't move ?
    This is unusual? Hope it get back in the 15 tomorrow.
  • D
    Dick
    Dick
    John DiBella is an excellent choice for a senior management position. He always stays engaged to the needs of the company and pays attention to detail. His contribution will assure continued growth of SLP.
  • d
    dale
    dale
    Ugly day today.. Can't really find any reason but this does seem to happen with regularity..
  • T
    Tim
    Tim
    Market likes the news on the new corporate structure. Shows continued strategic planning -
  • C
    Calvin
    Calvin

    Found a great no fee daytrading newsletter, vist www.T0pm@rketgainers.c0m and sign up...so glad I did.

  • C
    Chancellor
    Chancellor
    Whoa ... 10% drop in a week!
  • G
    Gustave
    Gustave

    Found a great no fee daytrading newsletter, vist www.PennySt0ckl0l.org and sign up...so glad I did

    Loading...
    www.PennySt0ckl0l.org
  • Q
    QuackQuack
    QuackQuack
    Wow, I caught the low of the day today, $13.85 on my latest addition to my very long SLP portfolio. I don't know why it went on sale, but I like it!
  • D
    Dick
    Dick

    Täglich has an updated research report:
    Maintaining Buy rating and increasing our 12-month price target to $17.35 per share from $13.35 due to increased sector valuation and forecasted EPS growth to FY19.
    SLP’s long-term growth should be driven by the increased use of software tools and consulting analytics for drug discovery, as well as the expansion, integration, and development of new products from the acquisition of Cognigen Corp. in FY15 and the 4Q17 acquisition of DILIsym Services, Inc.
    On June 1, 2017 the company acquired North Carolina based DILIsym Services, Inc., a provider of drug- induced liver injury simulation software and related consulting services. In calendar 2016, DILIsym generated net earnings of approximately $720,000 on revenue in excess of $3 million.
    SLP has penetrated nearly 20% of the pharmaceutical, biotechnology, and generic companies that would be potential users of its software and/or consulting services. In April 2017, an agreement with Quantum Bio Solutions of South Korea gave SLP the opportunity to sell its software tools to at least 40 new organizations.
    3Q17 EPS (reported 7/10/17) was $0.12 per share, on a 12.2% rise in sales to $6.7 million. We forecasted sales of $6.5 million and EPS of $0.11. In the year-ago period, SLP reported EPS of $0.11 on sales of $6 million
    We increase our FY17 sales and EPS forecasts to $22.9 million (prior was $22 million) and $0.32 per share (prior was $0.31) due to 3Q17 results and the anticipated 4Q17 contribution from the acquisition of DILIsym.
    For FY18, we increased by $0.04 per share our EPS projection to $0.40 on sales growth of 19% to $27.2 million (prior was $24.2 million) due to a full year contribution from DILIsym.
    In FY19, we project EPS of $0.48 per share on sales growth of 10.5%. Our accelerated EPS growth forecast reflects an increase in software customers and consulting services reaching at least 33% of total sales.
    See the full report at:
    http://www.taglichbrothers.com/companyreports/simplus/simplus-07192017.pdf

  • D
    Dick
    Dick

    Another great earnings conference call ! This is an exciting time to be a stockholder in SLP. A transcript of the call is available at this link: https://finance.yahoo.com/news/edited-transcript-slp-earnings-conference-062156641.html
    You can also see/hear the presentation at:http://www.simulations-plus.com/investorscorporate-profile/conference-calls/

    Edited Transcript of SLP earnings conference call or presentation 10-Jul-17 8:15pm GMT
    Q3 2017 Simulations Plus Inc Earnings Call
    finance.yahoo.com
  • Q
    QuackQuack
    QuackQuack
    Earnings release has propelled the bid to $14.00 after hours July 10, 2017. Congratulations to all patient investors. Thank you SLP team!
  • D
    Dick
    Dick
    I saw some after hours trades at $15.00 Thank you team SLP !
    And it will get even better... The DILIsym acquisition did $720,000 in net income last year and is now part of SLP. You can be sure that DILIsym will grow over time just as SLP has been doing. We might see $1 Million in additional profit in the the next 12 months just from DILIsym. I am still holding all my shares.
  • a
    arak1147
    arak1147
    Any ideas on why the big volume spike at the end of the trading day Friday 6-23-17 ?
  • D
    Dick
    Dick
    Another day of very high volume.That's always good when the share price is going up !
    Our little company continues to grow... Market cap is now over $120 Million. That's a HUGE increase since the dot com bust when we were a paltry $4 million or less.
    As far as the insider selling goes my thoughts are as follows: The used to be director sales don't mean a thing. The Grasela sales are part of a 10b5-1 trading plan which means the transactions take place regardless of anything going on at the company. The sale by Walt is well... Highly justified after putting his entire life into making this business a huge success. To be really honest he has been a rare CEO that has always put the shareholders first. He deserves it. I can't thank him enough for the fabulous success I have had in my IRA. SLP has been the main driver over the years that has resulted in gains for me far above the market averages. I have been a shareholder for about 15 years and still see good things happening so I continue to hold all my shares.
  • D
    Dick
    Dick
    There is a bid this morning at $11.80 for 100,000 shares. Somebody wants more.
  • J
    John
    John

    Courage is very important. Like a muscle, it is strengthened by use.http://dataunion.tistory.com/8607

    Simulations Plus NASDAQ $SLP Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.7 In other words, the correlation coefficient of the other stoc
    dataunion.tistory.com
  • a
    arak1147
    arak1147
    Wonder why all the recent insider share selling. Most sales are relatively small, but still unusual.

    Hard to believe this atypical activity within a short time frame is all a coincidence.
  • D
    Dick
    Dick

    Simulations Plus to Acquire DILIsym Services, Inc.
    This acquisition seems to be a perfect fit for the Simulations Plus business model.
    DILIsym Services, Inc. (“DILIsym Services”) will become a wholly owned subsidiary of Simulations Plus, Inc. (“Simulations Plus”) and will continue to operate under the DILIsym Services name. This accretive acquisition will result in the total number of Simulations Plus employees increasing from 68 to 79, and is expected to add more than $3 million to the revenues of the combined company in the coming fiscal year 2018.
    Simulations Plus will pay the shareholders of DILIsym Services cash consideration of up to $10 million, comprised of $5 million up front plus an earn-out of up to an additional $5 million over the next three years, based on the profitability of the DILIsym Services division. The Agreement provides that $1 million of the total up-front consideration will be held back for 18 months to satisfy any indemnifiable claims that may arise pursuant to the terms of the Agreement.
    For calendar year 2016, its most recent fiscal year, DILIsym Services, Inc. revenues were just over $3 million with net earnings of approximately $720,000. More information is available on the company’s Web site at https://www.dilisym.com.
    The complete release is at the link:
    https://www.sec.gov/Archives/edgar/data/1023459/000168316817001055/simulations_8k-ex9901.htm
    This is another example of how the SLP management team is doing an excellent job of using resources wisely and to the advantage of the stockholders. SLP stock is valued at approximately 10 X sales and they are buying a company for about 3 X sales. And the acquisition is immediately accretive resulting in about 4-5 cents per share increase in SLP earnings. Another job well done. Thanks to the hard working team at Simulations Plus. I am happy to be a shareholder.

  • D
    Dick
    Dick

    Täglich has a new research report update on SLP.
    Keep in mind this update was made before the acquisition was announced today.

    Key Investment Considerations:
    Maintaining Buy rating and increasing our 12-month price target to $13.35 per share from $12.30 due to increased sector and SLP’s valuations, partly restrained by a minimal reduction in our FY18 forecast.
    SLP’s long-term growth should be driven by the use of software tools and analytics for drug discovery and development increases, expansion of the acquired Cognigen Corp. business, and development of new solutions for clients’ research and development programs.
    In April 2016 a $4.7 million, five-year contract was signed by a major research foundation for Cognigen’s KIWI cloud-based software collaboration platform. The platform will be used for the foundation’s global teams engaged in model based drug development.
    SLP has penetrated nearly 20% of the pharmaceutical, biotechnology, and generic companies that would be potential users of its software and/or consulting services. In April 2017, an agreement with Quantum Bio Solutions of Korea gave SLP the opportunity to sell its software tools to at least 40 new organizations in Korea.
    2Q17 EPS (reported 4/10/17) was flat at $0.07, on a 10.5% rise in sales to $5.7 million. We forecasted sales of $5.5 million and EPS of $0.08.
    Our FY17 sales and income forecasts are largely unchanged at $22 million and $2.6 million or $0.31 per share.
    For FY18, we reduced by $0.01 per share our EPS projection to $0.36 on sales growth of 10% to $24.2 million (prior was $24.5 million) due primarily to new customer growth falling short of our prior forecast (125 vs. 150 in January 2017). The decrease in our customer forecast reflects a slower than anticipated ramp of the company’s PKPlusTM software offering (launched in 4Q16), partly offset by growth in consulting services.
    Maintaining Buy rating due to SLP’s growth potential, which should be sustained due to the increasing use of software tools and analytics for drug discovery and development, and leveraging the acquisition of Cognigen Corp. The collaboration between Cognigen and SLP scientists has resulted in new and innovative solutions for its clients’ research and development programs. The acquisition and growing client base should underlie accelerating net income growth in FY18.
    Full report is available at:
    http://www.taglichbrothers.com/companyreports/simplus/simplus-04242017.pdf

  • Q
    QuackQuack
    QuackQuack
    SLP hit a new high yesterday, will it hold this time? Been here for ten years, a long-term investment in a solid company. Regards to Mr. Milde.